Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Children's Hospital of Philadelphia
Ohio State University Comprehensive Cancer Center
First Affiliated Hospital of Zhejiang University
M.D. Anderson Cancer Center
St. Justine's Hospital
Georgetown University
Dana-Farber Cancer Institute
Medical College of Wisconsin
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
University of Chicago
Memorial Sloan Kettering Cancer Center
Karolinska University Hospital
Dana-Farber Cancer Institute
City of Hope Medical Center
University of Nebraska
Thomas Jefferson University
Dana-Farber Cancer Institute
Children's Hospital of Philadelphia
Beijing GoBroad Hospital
Massachusetts General Hospital
The Methodist Hospital Research Institute
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Alabama at Birmingham
University of Chicago
University of Chicago
Massachusetts General Hospital
Dana-Farber Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
Penn State University
Columbia University
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Zhejiang University
Children's Hospital of Philadelphia
University of Miami
City of Hope Medical Center
M.D. Anderson Cancer Center
Children's Hospital Medical Center, Cincinnati
Seattle Children's Hospital
Essen Biotech
Ege University
Nantes University Hospital
Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud - IDCBIS
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
Washington University School of Medicine